Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.35 |
| ▸ | GLRB | P48167 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14684024 | 0.83 | ALDH1A1 (0.41) | HCAR2MAPK1KMT2ACNR2ALDH1A1 | |
| SCHEMBL2678390 | 0.82 | ALDH1A1 (0.37) | MAPK1KMT2ACNR2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5010782 | 0.80 | ALDH1A1 (0.36) | MAPK1KMT2ACNR2KDM4EALDH1A1 | |
| SCHEMBL15759484 | 0.79 | POLB (0.40) | CNR2ALDH1A1PKMRXFP1 | |
| SCHEMBL21366412 | 0.79 | MAPK1 (0.41) | MAPK1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL14684006 | 0.77 | HCAR2 (0.32) | HCAR2MAPK1KMT2ACNR2 | |
| SCHEMBL15759485 | 0.77 | GSK3B (0.34) | MAPK1KMT2ACNR2ALDH1A1MAPT | |
| Bromide SCHEMBL15751628 | 0.76 | GSK3B (0.33) | KMT2ACNR2ALDH1A1MAPT | |
| SCHEMBL9963873 | 0.76 | PDPK1 (0.31) | CNR2PDPK1 | |
| SCHEMBL20711411 | 0.74 | HPGD (0.44) | KMT2AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3444251-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3080122-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
| EP-3080122-A1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Biogen MA Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| EP-2738163-A1 | AMIDINE COMPOUND OR SALT THEREOF | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-2738163-A1 | AMIDINE COMPOUND OR SALT THEREOF | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-0459244-B1 | Sulphonilised carboxylic acid amides | BAYER AG (DE) | 1996-02-28 | — | — | EP | disclosed |
| EP-0569810-A1 | Sulphonylamide herbicides | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| US-5256632-A | Pre- and postemergence | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-26 | — | — | US | disclosed |
| US-5205853-A | Premergence and postemergence herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| EP-0459244-A1 | Sulphonilised carboxylic acid amides | BAYER AG (DE) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318935-A1 | BIARYL BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | HCAR2 4064/4885MAPK1 618/4885KMT2A 1611/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | HCAR2 4117/4885MAPK1 626/4885KMT2A 1470/4885 |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | HCAR2 4064/4885MAPK1 618/4885KMT2A 1611/4885 |
| US-20140155597-A1 | AMIDINE COMPOUND OR SALT THEREOF | ERG28, ARG1, THEM6 | HCAR2 1856/4885MAPK1 51/4885KMT2A 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.